Subcutaneous lipoatrophy induced by long-term pegvisomant administration

Clinical Endocrinology

Volumn 70, Issue 4, 2009, Pages 655-656

  Salvatore, Cannavo ^a   Giovanni, Romanello ^a   Vittorio, Cavallari ^a   Claudio, Scisca ^a   Patrizia, Cannavo Serafinella ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGVISOMANT;

ACROMEGALY; ADULT; CASE REPORT; CAUCASIAN; DERMIS; ECHOGRAPHY; FEMALE; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LIPOATROPHY; LYMPHOCYTE; MAST CELL; PRIORITY JOURNAL; SKIN; ULTRASTRUCTURE;

ACROMEGALY; ADULT; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; LIPODYSTROPHY; SUBCUTANEOUS FAT;

EID: 61449187484     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03400.x     Document Type: Letter

References (5)

1. Schreiber, I., Buchfelder, M., Droste, M. et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology, 156, 75 82.
2. Muller, A.F., Kopchick, J.J., Flyvbjerg, A. et al. (2004) Growth hormone receptor antagonists. Journal of Clinical Endocrinology and Metabolism, 89, 1503 1511.
3. Roberts, M.J., Bentley, M.D. Harris, J.M. (2002) Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 54, 459 476.
4. Maffei, P., Martini, C., Pagano, C. et al. (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist Pegvisomant. Annals of Internal Medicine, 145, 310 312.
5. Marazuela, M., Daudèn, E., Ocòn, E. et al. (2007) Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Annals of Internal Medicine, 147, 741 743.